The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Multiple myeloma is a malignancy of terminally differentiated plasma cells, characterized by an extreme genetic heterogeneity that poses great challenges for its successful treatment. Due to antibody overproduction, MM cells depend on the precise regulation of the protein degradation systems. Despit...
Main Authors: | Tina Paradzik, Cecilia Bandini, Elisabetta Mereu, Maria Labrador, Elisa Taiana, Nicola Amodio, Antonino Neri, Roberto Piva |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/6/1235 |
Similar Items
-
Proteasome inhibitors: A rational for clinical use in the treatment of multiple myeloma
by: Petković Ivan, et al.
Published: (2016-01-01) -
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
by: Diego Acosta-Alvear, et al.
Published: (2015-09-01) -
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014-12-01) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01) -
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)